A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Leukemia
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence.[2] This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[3] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 3 · NCI website
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Before the tyrosine kinase inhibitor (TKI) era, allogeneic hematopoietic stem cell transplant (HSCT) was the primary treatment for children with chronic myeloid leukemia (CML). Published reports from this period described survival rates of 70% to 80% when an HLA–matched-family donor (MFD) was used in the treatment of children in early chronic phase. Lower survival rates were reported when HLA–matched-unrelated donors were used.[1-3]
Relapse rates were low (less than 20%) when transplant was performed in the chronic phase.[1,2] The primary cause of death was treatment-related mortality, which was increased with HLA–matched-unrelated donors compared with HLA-MFDs in most reports.[1,2] High-resolution DNA matching for HLA alleles appeared to reduce rates of treatment-related mortality, leading to improved outcome for HSCT using unrelated donors.[4]
Compared with transplant in the chronic phase, transplant in the accelerated phase or blast crisis and in the second chronic phase resulted in significantly reduced survival.[1-3] The use of T-lymphocyte depletion to avoid graft-versus-host disease resulted in a higher relapse rate and decreased overall survival,[5] supporting the contribution of a graft-versus-leukemia effect to favorable outcome after allogeneic HSCT.
The introduction of the TKI imatinib as a therapeutic drug targeted at inhibiting the BCR::ABL1 fusion kinase revolutionized the treatment of patients with CML, for both children and adults.[6] Most data on the use of TKIs for CML are from adult clinical trials. For more information, see Chronic Myeloid Leukemia Treatment. The more limited experience in children is described below.
Sources: 6 · Chronic Myeloid Leukemia Treatment
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Treatment options for children with chronic myeloid leukemia (CML) may include the following:
Tyrosine kinase inhibitor (TKI) therapy.
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
An increasing number of targeted agents are now approved for use in adults with CML. The use of these agents in pediatric patients is slow because there are not many studies that include children. Table 1 and the following narratives describe findings from specific trials where pediatric data are available.
Sources: Table 1
| Target and Agents | Prospective Pediatric Outcomes | Reference | ||||
|---|---|---|---|---|---|---|
| CHR | CCyR | MMR | PFS | |||
| ATP = adenosine triphosphate; CHR = complete hematologic response; CCyR = complete cytogenetic response; MMR = major molecular response; PFS = progression-free survival. | ||||||
| aAt 36 months. | ||||||
| bAt 12 months. | ||||||
| cAt 48 months. | ||||||
| dFor available active clinical trials using this agent, see the Treatment Options Under Clinical Evaluation section. | ||||||
| BCR::ABL1 kinase domain ATP-binding pocket: | ||||||
| Imatinib 260 mg/m2 | 98%a | 61% | 31%b | 98% | Giona et al.[1] | |
| Imatinib 340 mg/m2 | 91.5% | 66.6%b | Giona et al.[1] | |||
| Dasatinib 60–72 mg/m2 | 92%b | 52%b | 93%c | Gore et al.[2] | ||
| Nilotinib 230 mg/m2 | 64%b | Hijiya et al.[3] | ||||
| Bosutinib 400 mg/m2 | Phase I study only | Brivio et al.[4] | ||||
| Ponatinibd | Anecdotal data only | |||||
| BCR::ABL1 kinase domain myristoyl-binding pocket: | ||||||
| Asciminibd | No prospective pediatric data | |||||
Sources: Treatment Options Under Clinical Evaluation · 1 · 1 · 2 · 3 · 4
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Imatinib has shown a high level of activity in children with CML that is comparable with the activity observed in adults.[1,5-8] As a result of this high level of activity, it is common to initiate imatinib treatment in children with CML rather than proceeding immediately to allogeneic stem cell transplant.[9] The pharmacokinetics of imatinib in children appear consistent with previous results in adults.[10]
Doses of imatinib used in phase II trials for children with CML have ranged from 260 mg/m2 to 340 mg/m2, which provide comparable drug exposures as the adult flat-doses of 400 mg to 600 mg.[1,7,8]
Evidence (imatinib in children):
In a prospective trial, 44 pediatric patients with newly diagnosed CML were treated with imatinib (260 mg/day).[1]
Sources: 1
In a prospective trial, 44 pediatric patients with newly diagnosed CML were treated with imatinib (260 mg/day).[1]
The progression-free survival (PFS) rate was 98% at 36 months.
A complete hematologic response was achieved in 98% of the patients.
The rate of complete cytogenetic response was 61%, and the rate of major molecular response was 31% at 12 months. These are similar to the rates seen in adult patients with chronic-phase CML who were treated with imatinib.
In an Italian study, 47 pediatric patients with chronic-phase CML were treated with 340 mg/m2 per day of imatinib.[1]
Sources: 1
In an Italian study, 47 pediatric patients with chronic-phase CML were treated with 340 mg/m2 per day of imatinib.[1]
Complete cytogenetic response was achieved in 91.5% of patients at a median time of 6 months.
The rate of major molecular response (MMR) at 12 months was 66.6%.
Thus, it appears that starting with the higher dose of 340 mg/m2 has superior efficacy and is typically tolerable, with dose adjustment as needed for toxicity.[1,8]
Early molecular responses, such as the polymerase chain reaction (PCR)–based minimal residual disease (MRD) measurement at 3 months of therapy showing 10% BCR::ABL1 fusion transcripts, have been reported to be associated with improved PFS, similar to early molecular response data in adults.[11] The European LeukemiaNet (ELN) has defined optimal molecular milestones of BCR::ABL1 transcript levels to be 10% or less at 3 months, 1% or less at 6 months, and 0.1% or less at 12 months or more of therapy.[12]
The monitoring parameters described for adults with CML are reasonable to use in children. Monitoring occurs every 3 months until MMR is achieved and confirmed every 3 to 6 months thereafter. For more information, see Chronic Myeloid Leukemia Treatment.
Sources: Chronic Myeloid Leukemia Treatment
Imatinib is generally well tolerated in children. Adverse effects are generally mild to moderate and reversible with treatment discontinuation or dose reduction.[7,8] Growth delay occurs in most prepubertal children who receive imatinib.[13] Children who receive imatinib and experience growth impairment may show some catch-up growth during their pubertal growth spurts, but they are at risk of having lower-than-expected adult height, as most patients do not achieve midparental height.[13,14]
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Dasatinib is a TKI that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of children with CML.
Evidence (dasatinib in children):
A phase I trial of dasatinib in children showed that drug disposition, tolerability, and efficacy of this agent was similar to that observed in adults.[15,16]
A phase II trial of dasatinib, which included 84 children with newly diagnosed CML in chronic phase, used a dose of 60 mg/m2 (tablets) or 72 mg/m2 (oral solution) given to patients once daily.[2]
Sources: 2
A phase II trial of dasatinib, which included 84 children with newly diagnosed CML in chronic phase, used a dose of 60 mg/m2 (tablets) or 72 mg/m2 (oral solution) given to patients once daily.[2]
Complete cytogenetic response and MMR (≥3-log reduction or ≤0.1% on the International Scale [IS]) were achieved in 92% and 52% of patients, respectively, after 12 months of therapy.
The 4-year PFS rate was 93%.
Dasatinib was well tolerated, with very few grade 3 or grade 4 adverse events. No pleural or pericardial effusions or pulmonary complications were observed.
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Nilotinib is a TKI that is approved by the FDA for the treatment of children with CML.
Evidence (nilotinib in children):
The FDA approved nilotinib in March 2018 for the treatment of children with CML based on two sponsored trials.[3,17]
An initial study (NCT01077544 [CAMN107A2120]) of 11 patients evaluated pharmacokinetic, safety, and preliminary efficacy data.
Sources: NCT01077544
A second study (NCT01844765 [CAMN107A2203; AAML1321]) of 58 patients evaluated efficacy and safety.[3] Data from both studies were combined for a pooled-data analysis of 69 patients, which included 25 patients with newly diagnosed CML and 44 patients with resistant or intolerant CML. Both studies used a dose of 230 mg/m2 given twice daily (rounded to the nearest 50 mg; maximum single dose, 400 mg).[3,17]
Sources: NCT01844765 · 3 · 3 · 17
A second study (NCT01844765 [CAMN107A2203; AAML1321]) of 58 patients evaluated efficacy and safety.[3] Data from both studies were combined for a pooled-data analysis of 69 patients, which included 25 patients with newly diagnosed CML and 44 patients with resistant or intolerant CML. Both studies used a dose of 230 mg/m2 given twice daily (rounded to the nearest 50 mg; maximum single dose, 400 mg).[3,17]
In the phase II trial, 64% of patients with newly diagnosed CML achieved an MMR at 1 year.
The tolerability of nilotinib in children was similar to that observed in adults. Primary side effects affecting more than 30% of children included headache, fever, and hyperbilirubinemia.
Prolongation of QTc interval (defined in this trial as an increase of >30 msec over baseline) is a recognized side effect of nilotinib, and it was observed in 25% of children in these trials. The investigators recommended obtaining an electrocardiogram at baseline, 1 week, periodically afterward, and after dose adjustments.
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Most data on the use of TKIs for CML is from adult clinical trials. A safe pediatric dose has not yet been established for ponatinib.
Bosutinib is a TKI that targets the BCR::ABL1 gene fusion. The FDA approved bosutinib for the treatment of all phases of CML in adults who show intolerance to or whose disease shows resistance to previous therapy with another TKI.
The pediatric recommended phase II dose of bosutinib was determined in a phase I study that included 30 screened children, 28 of whom received treatment. For children previously resistant or intolerant to other TKIs, the dose was 400 mg/m2 with food once daily (maximum dose, 600 mg). For children with newly diagnosed CML, the dose was 300 mg/m2 with food once daily (maximum dose, 500 mg).[4]
Sources: 4
The most prevalent adverse event (all grades) was diarrhea, which occurred in 93% of the patients, 11% of whom had grade 3 or higher severity. In some cases, the diarrhea persisted for over 1 year of treatment.
Additional adverse events of all grades (although most were grades 1–2) that occurred in over 50% of the children included nausea, vomiting, and abdominal pain.
Fifteen children discontinued use of the agent (7 were intolerant and 8 had an inadequate response).
Responses to bosutinib were considered similar to other TKIs.
Ponatinib is a BCR::ABL1 fusion transcript inhibitor that is effective against the T315I variant.[18] Ponatinib induced objective responses in approximately 70% of heavily pretreated adults with chronic-phase CML. Responses were observed regardless of the baseline BCR::ABL1 kinase domain variant.[19] The use of ponatinib has been complicated by the high rate of vascular occlusion observed in patients receiving the agent. Arterial and venous thrombosis and occlusions (including myocardial infarction and stroke) occurred in more than 20% of treated patients.[20] Ponatinib is being prospectively studied in the pediatric population.
Asciminib is an allosteric inhibitor of the myristoyl-binding pocket, whereas the previously described TKI agents target the adenosine triphosphate (ATP)–binding pocket. Asciminib was initially used to treat adults with CML that had developed resistance to the ATP-binding pocket agents.[21] Asciminib was effective in this setting, and the FDA approved it to treat CML with the T315I variant.[22] Subsequently, asciminib was approved to treat adults with newly diagnosed CML because MMR, as well as time to MMR, was significantly better with asciminib than with imatinib, and it trended similarly compared with second-generation TKIs. Safety profiles were also better with asciminib.[23] To date, there are no prospectively reported pediatric data for asciminib.
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Discontinuation of TKI treatment is an accepted strategy for adults with CML who meet strict criteria related to their duration of treatment and response to treatment. Guidelines for discontinuation of TKIs have been developed by both the ELN and the U.S.-based National Comprehensive Cancer Network (NCCN).[12,24] Key elements for both guidelines include the following:
TKI therapy for a minimum duration of 4 to 5 years for ELN and 3 years for NCCN.
A minimum duration of deep molecular response (DMR or MR4) (BCR::ABL1 protein transcript level ≤0.01% IS) of 2 years for both ELN and NCCN.
These guidelines specify close monitoring of BCR::ABL1 transcript levels after TKI discontinuation. Loss of MMR (or MR3) (BCR::ABL1 transcript level ≤0.1% IS) is generally used as the trigger for reinitiation of TKI therapy.
Loss of MMR is most likely to occur within the first 6 months of TKI discontinuation. Loss of MMR occurs much less frequently more than 1 year after TKI discontinuation. A meta-analysis included 3,105 adult patients who initiated a first attempt at TKI discontinuation. The study found that the probability of molecular recurrence was 35% after 0 to 6 months, 8% after 6 to 12 months, 3% after 12 to 18 months, and 3% after 18 to 24 months.[25] These results indicated that approximately 50% of adult patients maintained their molecular responses 2 years after TKI discontinuation. Relapses can occur when TKIs have been discontinued for more than 2 years, but these recurrences appear to be infrequent (<2%). Unfavorable outcomes were uncommon when relapses occurred. In addition, 90% of patients reacquired deep molecular remission after TKI reinitiation.
Sources: 25
There are limited data regarding TKI discontinuation in children with CML. This limited experience is explained, in part, by the low incidence of CML in children. In addition, few children with CML who are treated with TKIs meet the criteria for TKI discontinuation. For example, among patients enrolled on the International Chronic Myeloid Leukemia Pediatric Study (I-CML-Ped [NCT01281735]), only 9% of children with CML who were treated with TKIs met the criteria for TKI discontinuation.[26] Other reports have also supported this trend.[27,28] Although the small number of children studied is a limitation, it appears that the outcome for TKI discontinuation in children with CML is similar to that of adults. Two of the larger pediatric studies that discuss this topic are summarized below:
Sources: I-CML-Ped [NCT01281735] · 26 · 27 · 28
The Japan Pediatric Leukemia and Lymphoma Study Group (JPLSG) reported on 22 children with CML who met their criteria for TKI discontinuation, which was similar to the NCCN's TKI discontinuation criteria.[28] The median age at CML diagnosis was 9 years, and the median age at TKI discontinuation was 16 years. The median duration of TKI therapy exceeded 8 years, and the median duration of MR4 before TKI discontinuation exceeded 4 years. Eleven of 22 children experienced loss of MMR at a median of 90 days after TKI discontinuation. All of these children subsequently regained MR4 after TKI resumption. The treatment-free remission rate at 12 months was 50%, and no relapses were observed beyond 4 months of TKI discontinuation.TKI withdrawal syndrome is observed in approximately 20% to 30% of adults when TKI therapy is discontinued.[29] The syndrome includes musculoskeletal pain that typically develops within 2 months of TKI discontinuation and continues for several months. The JPLSG study did not observe musculoskeletal pain in children after TKI discontinuation.
The International Registry of Childhood Chronic Myeloid Leukemia reported on 18 patients with CML who were younger than 18 years at diagnosis. These patients discontinued imatinib after meeting the criteria for TKI discontinuation (i.e., in chronic phase with a sustained DMR to imatinib [MR4; BCR::ABL1 transcript level ≤0.01% IS]) for at least 2 years.[26]Among the 18 children who stopped taking imatinib, 9 (50%) eventually resumed treatment.[26] Seven of these nine patients experienced loss of MMR (BCR::ABL1 transcript level ≤0.1% IS). Six of the seven patients regained MR4 within a median of approximately 5 months after TKI reinitiation. The remaining patient achieved MMR after TKI reinitiation. Two additional patients who had a one-log increase in BCR::ABL1 transcript levels, but did not meet the criteria for loss of MMR, were restarted on imatinib by their physicians. For the other nine patients who remained in treatment-free remission, the median follow-up period after imatinib discontinuation was 50 months. TKI withdrawal syndrome was not reported in any patients discontinuing imatinib.
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Treatment options for children with recurrent or refractory chronic myeloid leukemia (CML) may include the following:
Alternative tyrosine kinase inhibitor (TKI) therapy such as dasatinib, nilotinib, or bosutinib.
Sources: Alternative tyrosine kinase inhibitor (TKI) therapy
Allogeneic hematopoietic stem cell transplant (HSCT).
Sources: Allogeneic hematopoietic stem cell transplant (HSCT)
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
In children who develop a hematologic or cytogenetic relapse during treatment with imatinib or who have an inadequate initial response to their initial TKI agents, determination of BCR::ABL1 kinase domain variant status should be considered to help guide subsequent therapy. Depending on the patient’s variant status, alternative TKIs such as dasatinib, nilotinib, or bosutinib can be considered on the basis of the adult and pediatric experience with these agents.[1-6]
Evidence (dasatinib in children with resistant or intolerant CML):
In a study of 14 children with resistant or intolerant CML, the following results were observed:[6]
Sources: 6
In a study of 14 children with resistant or intolerant CML, the following results were observed:[6]
76% of patients were in complete cytogenetic remission, and 41% of patients had a major molecular response (MMR) after 12 months of dasatinib therapy.
The progression-free survival (PFS) rate was 78% at 48 months.
Evidence (nilotinib in children with resistant or intolerant CML):
In a study of 44 children with CML who were resistant or intolerant to imatinib or dasatinib, the following results were observed:[7]
Sources: 7
In a study of 44 children with CML who were resistant or intolerant to imatinib or dasatinib, the following results were observed:[7]
40.7% of patients achieved an MMR after 12 months of nilotinib therapy.
After a median of 11.3 months, no patients had experienced disease progression.
Dasatinib and nilotinib are active against many BCR::ABL1 variants that confer resistance to imatinib, although the agents are ineffective in patients with the T315I variant. In the presence of the T315I variant, which is resistant to all U.S. Food and Drug Administration (FDA)–approved TKIs, an allogeneic HSCT should be considered. Ponatinib, the BCR::ABL1 inhibitor effective against the T315I variant in adults, has not been prospectively studied in the pediatric population.
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
The question of whether a pediatric patient with CML should receive an allogeneic HSCT when multiple TKIs are available remains unanswered. However, reports suggest that PFS does not improve when using HSCT, compared with the sustained use of imatinib.[8] The potential advantages and disadvantages need to be discussed with the patient and family. While HSCT is currently the only known definitive curative therapy for CML, patients discontinuing treatment with TKIs after sustained molecular remissions, who remained in molecular remission, have been reported.[9]
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following are examples of national and/or institutional clinical trials that are currently being conducted:
NCT04925479 (Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia): This study aims to determine the dose and safety profile of asciminib in pediatric patients who were previously treated with one or more TKIs.
Sources: NCT04925479
NCT03934372 (An Open-Label, Single-Arm, Phase I/II Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas, or Solid Tumors in Pediatric Participants): This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 year to younger than 18 years.
Sources: NCT03934372
Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 5, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed chronic myelogenous leukemia (CML) may include the following:
Sources: diagnosed · chronic myelogenous leukemia
Targeted therapy with a tyrosine kinase inhibitor (imatinib, dasatinib, or nilotinib).
Sources: Targeted therapy · tyrosine kinase inhibitor · imatinib · dasatinib · nilotinib
A clinical trial to study the rate of CML recurrence after stopping tyrosine kinase inhibitor therapy, and the ability to achieve remission again if CML recurs in children with CML who are in remission for at least 2 years after receiving treatment with the same tyrosine kinase inhibitor for at least 3 years.
Sources: clinical trial · recurrence · remission
Treatment of refractory or recurrent childhood CML may include the following:
Sources: refractory · recurrent
Targeted therapy with a tyrosine kinase inhibitor (dasatinib or nilotinib).
Stem cell transplant using blood stem cells from a donor.
Sources: Stem cell transplant · blood stem cells · donor
Leukemia
ClinicalTrials.gov recordChronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
ClinicalTrials.gov recordChronic Myeloid Leukemia
ClinicalTrials.gov recordPhiladelphia Positive (Ph+) Chronic Myelogenous Leukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia,...
ClinicalTrials.gov recordPhiladelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia
ClinicalTrials.gov recordMyeloid Leukemia, Philadelphia Positive
ClinicalTrials.gov recordChronic Myeloid Leukemia in children and adolescents
1 INDICATIONS AND USAGE Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease,...
1 INDICATIONS AND USAGE Malignant Diseases FRINDOVYX is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma...
Treatment of Recurrent or Refractory Childhood CML
Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult patients with: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or...
DailyMed labelCyclophosphamide is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma,...
DailyMed labelMalignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular...
DailyMed labelCyclophosphamide is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma,...
DailyMed labelMalignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular...
DailyMed labelMalignant Diseases FRINDOVYX is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse),...
DailyMed label